JP2002255832A - Mineral absorption-promoting agent and anemia- improving agent - Google Patents
Mineral absorption-promoting agent and anemia- improving agentInfo
- Publication number
- JP2002255832A JP2002255832A JP2001052882A JP2001052882A JP2002255832A JP 2002255832 A JP2002255832 A JP 2002255832A JP 2001052882 A JP2001052882 A JP 2001052882A JP 2001052882 A JP2001052882 A JP 2001052882A JP 2002255832 A JP2002255832 A JP 2002255832A
- Authority
- JP
- Japan
- Prior art keywords
- yeast cell
- cell wall
- anemia
- yeast
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Seeds, Soups, And Other Foods (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、酵母細胞壁または
酵母細胞壁多糖類の新規な用途に関し、さらに詳細に
は、本発明は酵母細胞壁または酵母細胞壁多糖類を有効
成分として、優れたミネラル吸収促進作用ならびに貧血
の予防または改善作用を有する、食品および医薬組成物
に関する。また、ミネラル吸収促進作用、貧血予防また
は改善作用を有する、飲料や動物飼料に関する。The present invention relates to a novel use of a yeast cell wall or a yeast cell wall polysaccharide, and more particularly, the present invention relates to a method of using a yeast cell wall or a yeast cell wall polysaccharide as an active ingredient to provide an excellent mineral absorption promoting action. And a food and pharmaceutical composition having an anemia preventing or ameliorating effect. The present invention also relates to beverages and animal feeds having a mineral absorption promoting action and an anemia preventing or improving action.
【０００２】[0002]
【従来の技術】従来、日本人の鉄の摂取量は栄養必要量
を下回っており、男性で３５％、女性で６０％が所要量
を満たしていない（平成９年度国民栄養調査）。このよ
うに、体内において欠乏した鉄分を補給するためには、
一日要求量以上に多くの鉄を摂取する必要があるが、摂
取量を増加させるよりは、ミネラルの吸収率を高める方
が高率的である。従って、鉄の吸収性が高い食品ならび
に鉄の吸収を促進させる物質には高い関心が集まってい
る。一方、貧血の予防あるいは治療に用いられている鉄
化合物の製剤として種々の製剤が考案されているが、鉄
に起因する食欲不振、悪心、嘔吐、腹痛、便秘、下痢等
の消化器に対する副作用が臨床上の問題となっている。
そこで、天然物由来の安全性が高い、鉄の吸収促進作用
ならびに貧血症状の改善作用を有する食品、動物用飼料
または医薬組成物を提供することが望まれている。2. Description of the Related Art Conventionally, the intake of iron by Japanese is lower than the nutritional requirement, and 35% of men and 60% of women do not meet the required amount (1997 National Nutrition Survey). Thus, in order to replenish iron deficiency in the body,
It is necessary to consume more iron than required daily, but it is more efficient to increase the absorption rate of minerals than to increase the intake. Therefore, there is a great deal of interest in foods with high iron absorption and substances that promote iron absorption. On the other hand, various preparations have been devised as preparations of iron compounds used for the prevention or treatment of anemia.However, side effects on the digestive system such as anorexia, nausea, vomiting, abdominal pain, constipation, and diarrhea caused by iron have been devised. It is a clinical problem.
Therefore, it is desired to provide a food, animal feed or pharmaceutical composition having a high safety derived from natural products and having an iron absorption promoting action and an anemia ameliorating action.
【０００３】[0003]
【発明が解決しようとする課題】従って、本発明は酵母
細胞壁または酵母細胞壁多糖類を有効成分とした、副作
用がなく、安全性の高い、ミネラル吸収促進ならびに貧
血の予防または改善作用を有する食品、飲料、飼料なら
びに医薬組成物を提供することにある。SUMMARY OF THE INVENTION Accordingly, the present invention relates to a food containing a yeast cell wall or a yeast cell wall polysaccharide as an active ingredient, having no side effects, having high safety, promoting mineral absorption, and preventing or improving anemia. It is to provide drinks, feeds and pharmaceutical compositions.
【０００４】[0004]
【課題を解決するための手段】このような実情に鑑み、
本発明者らは鋭意研究を重ねた結果、酵母細胞壁または
酵母細胞壁多糖類がミネラルの吸収促進作用ならびに貧
血の予防及び改善作用を有することを見出し、本発明を
完成した。SUMMARY OF THE INVENTION In view of such circumstances,
As a result of intensive studies, the present inventors have found that yeast cell walls or yeast cell wall polysaccharides have a mineral absorption promoting action and an anemia preventing and improving action, and have completed the present invention.
【０００５】[0005]
【発明の実施の形態】本発明に用いる酵母細胞壁は生酵
母を自己消化もしくはプロテアーゼ、ヌクレアーゼ、エ
ステラーゼ、グルカナーゼ、リパーゼ等を添加した酵素
処理、あるいはいずれかを併用して細胞内の可溶性菌体
内成分を除去した抽出残さより得られる。このとき使用
する酵母はビール酵母、パン酵母、アルコール酵母、清
酒用酵母など一般に食品工業で用いられるものを使用す
る。原料入手の容易さではビール酵母、パン酵母、トル
ラ酵母を使用することが望ましい。酵素処理を速やかに
行うためにホモジナイザーなどにより物理的な破壊を細
胞壁に施してから菌体残さを得てもよい。必要に応じて
酵母の洗浄処理、ｐH、温度あるいは圧力の調整処理等
を加えて酵母細胞壁を得ることもできる。BEST MODE FOR CARRYING OUT THE INVENTION The yeast cell wall used in the present invention is obtained by autolyzing live yeast or treating it with an enzyme to which protease, nuclease, esterase, glucanase, lipase, or the like has been added, or by using any of these together in combination with soluble intracellular components. Is obtained from the extraction residue from which. The yeasts used at this time include those commonly used in the food industry, such as brewer's yeast, baker's yeast, alcoholic yeast, and yeast for sake. It is desirable to use brewer's yeast, baker's yeast, and torula yeast in terms of availability of raw materials. In order to carry out the enzyme treatment promptly, cell debris may be obtained after subjecting the cell wall to physical destruction using a homogenizer or the like. If necessary, a yeast cell wall can be obtained by subjecting the yeast to washing treatment, pH, temperature or pressure adjustment treatment, or the like.
【０００６】また、酵母の可溶性菌体内成分を除去して
得られた酵母細胞壁を酸またはアルカリ性の水溶液にて
処理し、さらに可溶性成分を除去した酵母菌体残さを調
製することもできる。具体的には、上記酵母細胞壁を0.
01〜２Nの塩酸、硫酸、硝酸等の酸で処理するか、0.01
〜２Nの水酸化ナトリウム、水酸化カリウム等のアルカ
リで処理した後、その懸濁液を遠心分離等により酵母菌
体残さを採取し調製することもできる。酸、アルカリ処
理の際に加熱を施してもよい。また、酸、アルカリ処理
後にエタノール等の溶媒により洗浄して酵母菌体残さを
得ることもできる。[0006] The yeast cell wall obtained by removing soluble intracellular components of yeast can be treated with an acid or alkaline aqueous solution to prepare yeast cell residues from which soluble components have been further removed. Specifically, the yeast cell wall was treated with 0.
Treat with 01 ~ 2N acid such as hydrochloric acid, sulfuric acid, nitric acid or 0.01
After treating with ~ 2N alkali such as sodium hydroxide and potassium hydroxide, the suspension can be prepared by collecting the yeast cell residue by centrifugation or the like. Heating may be performed during acid or alkali treatment. After treatment with an acid or an alkali, the residue may be washed with a solvent such as ethanol to obtain a yeast cell residue.
【０００７】本発明に用いる酵母細胞壁多糖類は D.J.M
annersら (Biochem. J., 135, 19(1973))、 D.H.Northc
oatら (Biochem. J. 51, 232 (1952))、前田ら（特開平
4−66546）の方法により得ることができる。なお、酵母
細胞壁多糖類の採取はこの方法に限られない。酵母細胞
壁および酵母細胞壁多糖類は、一般に使用される担体、
助剤、添加剤等とともに製剤化することができ、常法に
従って経口の製品として人間を含む動物の医薬品として
用いることができる。また、人間を含む動物の食品素材
として混合してそれらの飲食品とすることができる。The yeast cell wall polysaccharide used in the present invention is DJM
anners et al. (Biochem. J., 135, 19 (1973)), DHNorthc
oat et al. (Biochem. J. 51, 232 (1952)), Maeda et al.
4-66546). In addition, collection of yeast cell wall polysaccharide is not limited to this method. Yeast cell walls and yeast cell wall polysaccharides are commonly used carriers,
It can be formulated together with auxiliaries, additives and the like, and can be used as an oral product as a drug for animals including humans according to a conventional method. In addition, they can be mixed as food materials of animals including humans to obtain foods and drinks.
【０００８】酵母細胞壁を有効成分とするミネラル吸収
促進作用ならびに貧血の予防または改善作用は、医薬品
として用いるときは経口剤として製剤、カプセル剤、顆
粒剤、シロップ剤などとして用いることができる。例え
ば、錠剤の場合には1日あたり２mg〜1000mg／kg体重の
量、好ましくは10mg〜200mg／kg体重の量を１ないしは
数回投与し、十分にその効果を奏し得るものである。[0008] The effect of promoting mineral absorption and preventing or ameliorating anemia using the yeast cell wall as an active ingredient can be used as an oral preparation, such as a preparation, capsule, granule, syrup and the like when used as a pharmaceutical. For example, in the case of a tablet, an amount of 2 mg to 1000 mg / kg body weight per day, preferably 10 mg to 200 mg / kg body weight, is administered one or several times, and the effect can be sufficiently exerted.
【０００９】本発明の医薬品は生理的に認めうるベヒク
ル、担体、賦形剤、統合剤、安定剤、香味剤等とともに
要求される単位容量形態を取ることができる。錠剤、カ
プセル剤に混和される佐薬は次のようなものである。ト
ロガント、アラビアゴム、コーンスターチ、ゼラチンの
ような結合剤、微晶性セルロースのような膨化剤、ステ
アリン酸マグネシウムのような滑沢剤、蔗糖、乳糖、サ
ッカリンのような甘味剤、ペパーミント、アカモノ油、
チェリーのような香味剤など。また、カプセル剤の場合
は上記材料にさらに油脂のような液体担体を含有するこ
とができ、また、他の材料は被覆剤として、または製剤
の物理的形態を別な方法で変化させることができる。例
えば、錠剤はシェラック、砂糖で被覆することができ
る。甘味料としてシロップまたはエリシキル剤、蔗糖、
防腐剤としてメチルまたはプロピルパラベン、色素およ
びチェリーまたはオレンジ香味のような香味剤を含有す
ることができる。本発明の飲食品は上記製剤の形態でも
良いが、あめ、煎餅、クッキー、飲料などの形態でそれ
ぞれの食品原料に所要量を加えて、一般の製造法により
加工製造することもできる。健康食品、機能性食品とし
ての摂取は、病気予防、健康維持に用いられるので、経
口摂取として1日数回に分けて、全日量として0.1ｇ〜10
0g、好ましくは0.5〜20gを含む加工品として摂取され
る。The pharmaceutical preparation of the present invention can take the required unit dosage form together with physiologically acceptable vehicles, carriers, excipients, integrating agents, stabilizers, flavoring agents and the like. The adjuvants mixed with tablets and capsules are as follows. Binders such as troganants, gum arabic, corn starch, gelatin, leavening agents such as microcrystalline cellulose, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose, saccharin, peppermint, reddish oil,
Flavors such as cherry. In the case of capsules, the above materials may further contain a liquid carrier such as an oil or fat, and other materials may change the physical form of the formulation as coatings or in other ways. . For example, tablets may be coated with shellac, sugar. Syrup or elixir, sucrose,
Preservatives may include methyl or propyl parabens, dyes and flavoring agents such as cherry or orange flavor. The food and drink of the present invention may be in the form of the above-mentioned preparations, but may also be processed and manufactured by a general manufacturing method by adding a required amount to each food material in the form of candy, rice crackers, cookies, beverages and the like. Ingestion as a health food or functional food is used for disease prevention and health maintenance, so it is divided into several times a day for oral intake, and the total daily amount is 0.1 g to 10 g.
It is ingested as a processed product containing 0 g, preferably 0.5 to 20 g.
【００１０】[0010]
【発明の効果】本発明は酵母細胞壁または酵母細胞壁多
糖類を有効成分とした、ミネラル吸収促進剤ならびに貧
血改善剤である。このミネラル吸収促進剤ならびに貧血
改善剤は生体にとって安全性が高く、かつ加工特性に優
れているので、これを配合した食品あるいは医薬品等の
組成物は、日常の食生活を通して摂取することが可能で
あり、貧血の予防や改善ができる。Industrial Applicability The present invention is a mineral absorption promoter and an anemia ameliorating agent comprising yeast cell wall or yeast cell wall polysaccharide as an active ingredient. Since the mineral absorption enhancer and the anemia ameliorating agent are highly safe for living organisms and have excellent processing characteristics, a composition such as a food or a pharmaceutical containing the same can be ingested through a daily diet. Yes, it can prevent and improve anemia.
【００１１】[0011]
【実施例】次に、実施例を挙げて本発明を詳細に説明す
るが、本発明はこれら実施例に限定されるものではな
い。 実験例１：酵母細胞壁の生成 酵母細胞壁はビール酵母スラリーをpH10に調整した活性
ソーダ溶液と50秒間接触させ、脱苦味したものを水洗
し、pH３〜８、50〜70℃で一晩放置して完全に自己消化
させ、水に可溶化した成分を水で抽出除去し、噴霧乾燥
して得た。10％酵母スラリー10kgから460gの酵母細胞壁
が得られた。Next, the present invention will be described in detail with reference to examples, but the present invention is not limited to these examples. Experimental Example 1: Formation of yeast cell wall The yeast cell wall was brought into contact with an activated soda solution adjusted to pH 10 for 50 seconds by brewer's yeast slurry, and the bitter taste was washed with water and left overnight at pH 3 to 8 and 50 to 70 ° C. The components that were completely autolyzed and solubilized in water were extracted and removed with water and spray-dried. 460 g of yeast cell wall was obtained from 10 kg of 10% yeast slurry.
【００１２】実験例２：酵母細胞壁多糖類の生成 実験例１で得られた酵母細胞壁１kgを溶媒水で常圧、10
0℃、16時間加熱処理後、遠心分離（8000rpm、15分）に
よって得られた水溶性画分をセライト濾過した。その濾
過液を減圧濃縮（約20〜30倍濃縮）後、4℃で一昼夜放
置し、冷凝固物を除去した。その濃縮液に２倍量のエタ
ノールを加えて多糖成分の沈殿物を得た。その沈殿物を
凍結乾燥し、白色の粉末13ｇを得た。Experimental Example 2: Production of yeast cell wall polysaccharide 1 kg of the yeast cell wall obtained in Experimental Example 1 was dissolved in a solvent water at normal pressure and under pressure.
After heat treatment at 0 ° C. for 16 hours, the water-soluble fraction obtained by centrifugation (8000 rpm, 15 minutes) was filtered through celite. The filtrate was concentrated under reduced pressure (approximately 20 to 30-fold concentration), and then allowed to stand at 4 ° C. for 24 hours to remove cold coagulated material. To the concentrated solution, twice the amount of ethanol was added to obtain a precipitate of a polysaccharide component. The precipitate was freeze-dried to obtain 13 g of a white powder.
【００１３】実施例１：鉄の吸収促進作用の検討 実験例１で得た酵母細胞壁を用いた。4週齢のウイスタ
ー系雄性ラットを用いて検討した。１週間予備飼育後、
5週齢より表１に示す試験飼料を自由に与えた。各飼料
中のミネラル含量は酵母細胞壁に含まれるミネラル量を
考慮して調整した（表２）。飼料投与開始10日から14日
目の４日間の糞を採取し、糞中に排泄された鉄含量を測
定した。見かけの吸収率は以下の式により算出した。 見かけの吸収率（％）＝［（摂取した飼料中の鉄量−排
泄された糞中の鉄量）／（摂取した飼料中の鉄量）］×
100 鉄の見かけの吸収率を表３に示した。試験群は対照群と
比較して鉄の吸収が促進された。Example 1 Examination of the Effect of Promoting Iron Absorption The yeast cell wall obtained in Experimental Example 1 was used. The study was performed using 4-week-old male Wistar rats. After pre-breeding for one week,
From the age of 5 weeks, the test feeds shown in Table 1 were freely given. The mineral content in each feed was adjusted in consideration of the amount of mineral contained in the yeast cell wall (Table 2). Feces were collected for 4 days from the 10th to 14th day from the start of feed administration, and the iron content excreted in the feces was measured. The apparent absorption was calculated by the following equation. Apparent absorption rate (%) = [(amount of iron in ingested feed-amount of iron in excreted feces) / (amount of iron in ingested feed)] x
Table 3 shows the apparent absorption of 100 iron. The test group had enhanced iron absorption compared to the control group.
【００１４】[0014]
【表１】 [Table 1]
【００１５】[0015]
【表２】 [Table 2]
【００１６】[0016]
【表３】 [Table 3]
【００１７】実施例２：貧血改善効果の検討 (ａ)６週齢のウイスター系雄性ラットを用いて検討し
た。３日間予備飼育後、表４に示す鉄欠乏飼料（３mg／
kg Fe）を28日間自由に与え、鉄欠乏性貧血ラットを作
成した。ラットは血液性状（ヘモグロビン（Hb）濃度、
ヘマトクリット値（Ht）、血清鉄濃度（SI））により４
つの群に分け、表５に示す試験飼料（各試験飼料の鉄含
量は66.4mg／kgとなるようにFeSO4 ・７H2Oにて調整し
た）を自由に与えた。なお、乾燥酵母には酵母細胞壁成
分が含まれている日本薬局方乾燥酵母を用いた。酵母エ
キスにはス−パーミーストＲ−1（商品名、アサヒビー
ル食品株式会社）を用いたが、これには酵母細胞壁成分
は含まれていない。酵母細胞壁には実施例１で生成した
ものを用いた。投与14日目に血液性状を測定し、ヘモグ
ロビン再生率（HRE）を算出した。［参考文献：K.J.H.W
ienk et al., Eur. J. Nutr., 38, 51-75 (1999)］。 ヘモグロビン再生率（％）＝｛（投与14日目の全ヘモグ
ロビン鉄量（mg））−（投与0日目の全ヘモグロビン鉄
量（mg））｝÷（0日目から14日目までに吸収された鉄
量）×100 全ヘモグロビン鉄（mg）＝ヘモグロビン（mg／L）×体
重（kg）×ヘモグロビン中の鉄含量率（0.335％）×血
液量率（体重の6.7％） 試験結果を表６に示す。飼料投与開始時に対する14日目
のヘモグロビン濃度の増加量およびヘモグロビン再生率
において、乾燥酵母を含む飼料を給餌した試験群１、お
よび酵母細胞壁を含む飼料を給餌した試験群３には、有
意な増加が見られ、貧血の改善が確認された。Example 2: Examination of anemia ameliorating effect (a) Examination was performed using 6-week-old male Wistar rats. After preliminary breeding for 3 days, an iron-deficient diet (3 mg /
kg Fe) for free for 28 days to produce iron-deficient anemic rats. Rats have blood characteristics (hemoglobin (Hb) concentration,
Hematocrit value (Ht), serum iron concentration (SI))
One divided into groups of test feed shown in Table 5 (iron content of each test feed was adjusted by FeSO 4 · 7H 2 O so as to be 66.4 mg / kg) was given freely. In addition, the dried yeast used the dry yeast of the Japanese Pharmacopoeia which contains a yeast cell wall component. Super yeast R-1 (trade name, Asahi Breweries, Ltd.) was used as the yeast extract, but it did not contain yeast cell wall components. The yeast cell wall used in Example 1 was used. On the 14th day after administration, blood properties were measured, and the hemoglobin regeneration rate (HRE) was calculated. [Reference: KJHW
ienk et al., Eur. J. Nutr., 38, 51-75 (1999)]. Hemoglobin regeneration rate (%) = {(total hemoglobin iron on day 14 of administration (mg))-(total hemoglobin iron on day 0 of administration (mg))｝ ÷ (absorbed from day 0 to day 14) Iron content) x 100 total hemoglobin iron (mg) = hemoglobin (mg / L) x body weight (kg) x iron content in hemoglobin (0.335%) x blood volume rate (6.7% of body weight) 6 is shown. The increase in hemoglobin concentration and hemoglobin regeneration rate on the 14th day from the start of feed administration was significantly increased in Test Group 1 fed with feed containing dry yeast and Test Group 3 fed with feed containing yeast cell walls. Was observed, and improvement of anemia was confirmed.
【００１８】[0018]
【表４】 [Table 4]
【００１９】[0019]
【表５】 [Table 5]
【００２０】[0020]
【表６】 [Table 6]
【００２１】（ｂ）６週齢のウイスター系雄性ラットを
用いて検討した。３日間予備飼育後、表７に示す鉄欠乏
飼料（３mg／kg Fe）を1日に10ｇ与え、1時間以内に摂
食できるように10日間訓練しながら、鉄欠乏性貧血モデ
ルラットを作成した。ラットは血液性状（ヘモグロビン
（Hb）濃度、ヘマトクリット値（Ht）、血清鉄濃度（S
I））により４つの群に分け、表８に示す試験飼料（各
試験飼料の鉄含量は200.0mg／kgとなるようにFeSO4 ・
７H2Oにて調整した）10ｇを与え、投与前、投与30、9
0、240分後の血清鉄濃度（SI）を測定し、体内への鉄の
吸収について検討した。なお、乾燥酵母および酵母エキ
スは前述のものと同じものを用いた。酵母細胞壁には実
施例１で生成したものを用いた。血清鉄濃度の経時的変
化を表9に示した。酵母細胞壁を含む飼料を給餌した試
験群３は、他の試験群に比べ、投与30、90分後の血清鉄
濃度が上昇しており、体内への鉄の吸収が高まっている
ことが認められた。(B) Examination was performed using 6-week-old male Wistar rats. After pre-breeding for 3 days, an iron-deficient anemia model rat was prepared by feeding 10 g of an iron-deficient feed (3 mg / kg Fe) shown in Table 7 per day and training for 10 days to be able to eat within 1 hour. . Rats have blood characteristics (hemoglobin (Hb) concentration, hematocrit value (Ht), serum iron concentration (S
I)) and divided into four groups. The test feeds shown in Table 8 (FeSO 4.
(Adjusted with 7H 2 O) 10 g before administration, administration 30 and 9
The serum iron concentration (SI) at 0 and 240 minutes was measured, and the absorption of iron into the body was examined. The same dry yeast and yeast extract as those described above were used. The yeast cell wall used in Example 1 was used. Table 9 shows the change over time in the serum iron concentration. In the test group 3 fed the feed containing the yeast cell wall, the serum iron concentration was increased 30 and 90 minutes after administration, and the absorption of iron into the body was increased, compared to the other test groups. Was.
【００２２】[0022]
【表７】 [Table 7]
【００２３】[0023]
【表８】 [Table 8]
【００２４】[0024]
【表９】 [Table 9]
【００２５】実施例３:酵母細胞壁の医薬品への応用 １）錠剤、カプセル製剤 酵母細胞壁 10.0ｇ 乳糖 75.0ｇ ステアリン酸マグネシウム 15.0ｇ 合計 100.0ｇ 上記の各重量部を均一に混合し、常法に従って錠剤、カ
プセル剤とした。 ２）散剤、顆粒剤 酵母細胞壁 20.0ｇ 澱粉 30.0ｇ 乳糖 50.0ｇ 合計 100.0ｇ 上記の各重量部を均一に混合し、常法に従って散剤、顆
粒剤とした。Example 3 Application of Yeast Cell Wall to Pharmaceuticals 1) Tablet and Capsule Preparation Yeast Cell Wall 10.0 g Lactose 75.0 g Magnesium Stearate 15.0 g Total 100.0 g And capsules. 2) Powders and granules Yeast cell wall 20.0 g Starch 30.0 g Lactose 50.0 g Total 100.0 g The above parts by weight were uniformly mixed to obtain powders and granules according to a conventional method.
【００２６】実施例４：酵母細胞壁の食品への応用 １）飴 酵母細胞壁 0.10ｇ 蔗糖 19.30ｇ 水飴 70.00ｇ 水 9.00ｇ 着色料 0.55ｇ 香料 0.05ｇ 合計 100.0ｇ 上記の各重量部を均一に混合し、常法に従って飴とし
た。 ２）クッキー 酵母細胞壁 1.0ｇ 薄力粉 30.0ｇ コーンスターチ 10.0ｇ 全卵 15.0ｇ バター 16.0ｇ 砂糖 22.0ｇ 水 5.8ｇ ベーキングパウダー 0.2ｇ 合計 100.0ｇ 上記の各重量部を均一に混合し、常法に従ってクッキー
とした。Example 4: Application of yeast cell wall to food 1) Candy yeast cell wall 0.10 g sucrose 19.30 g syrup 70.00 g water 9.00 g Colorant 0.55 g Flavor 0.05 g Total 100.0 g The above parts by weight are mixed uniformly. And made into candy according to the usual method. 2) Cookies Yeast cell wall 1.0 g Soft flour 30.0 g Corn starch 10.0 g Whole egg 15.0 g Butter 16.0 g Sugar 22.0 g Water 5.8 g Baking powder 0.2 g Total 100.0 g Each of the above parts by weight was uniformly mixed and made into cookies according to a conventional method. .
【００２７】実施例５：酵母細胞壁多糖類の食品への応
用 １）スープ マンナン 1.0ｇ スイートコーン（クリームタイプ）19.0ｇ バター 4.0ｇ 小麦粉 3.0ｇ ブイヨンスープ 32.5ｇ 牛乳 32.5ｇ 生クリーム 8.0ｇ 合計 100.0ｇ 上記の各重量部を均一に混合し、常法に従ってスープと
した。なお、マンナンは酵母細胞壁多糖類から生成した
ものを用いた。 ２）ジュース マンナン 1.00ｇ 濃縮ミカン果汁 15.00ｇ 果糖 5.00ｇ クエン酸 0.20ｇ 香料 0.10ｇ 色素 0.15ｇ アスコルビン酸ナトリウム 0.05ｇ 水 78.50ｇ 合計 100.0ｇ 上記の各重量部を均一に混合し、常法に従ってジュース
とした。なお、マンナンは酵母細胞壁多糖類から生成し
たものを用いた。Example 5: Application of yeast cell wall polysaccharide to food 1) Soup mannan 1.0 g Sweet corn (cream type) 19.0 g Butter 4.0 g Flour 3.0 g Bouillon soup 32.5 g Milk 32.5 g Fresh cream 8.0 g Total 100.0 g The above parts by weight were uniformly mixed to obtain a soup according to a conventional method. The mannan used was produced from yeast cell wall polysaccharide. 2) Juice Mannan 1.00 g Concentrated orange juice 15.00 g Fructose 5.00 g Citric acid 0.20 g Flavor 0.10 g Dye 0.15 g Sodium ascorbate 0.05 g Water 78.50 g Total 100.0 g Mix the above parts by weight and juice according to the usual method And The mannan used was produced from yeast cell wall polysaccharide.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ２３Ｌ 1/28 Ａ２３Ｌ 1/28 Ｚ ４Ｂ０３６ 1/39 1/39 ４Ｃ０８７ 2/52 2/38 Ｇ 2/38 Ａ６１Ｐ 3/00 Ａ６１Ｐ 3/00 7/06 7/06 43/00 １０５ 43/00 １０５ Ａ２３Ｌ 2/00 Ｆ Ｆターム(参考） 2B150 AB20 AC24 BB03 DD11 DD17 4B014 GB07 GG18 GK06 GL11 4B017 LC03 LK13 LK21 LL09 4B018 MD33 MD81 ME14 4B032 DB21 DK14 DK54 DL20 4B036 LC06 LF01 LH11 LH48 LK06 4C087 AA01 AA02 BC11 CA09 CA14 CA47 ZA55 ZC01 ZC21 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification code FI Theme coat ゛ (Reference) A23L 1/28 A23L 1/28 Z 4B036 1/39 1/39 4C087 2/52 2/38 G 2/38 A61P 3/00 A61P 3/00 7/06 7/06 43/00 105 43/00 105 A23L 2/00 FF term (reference) 2B150 AB20 AC24 BB03 DD11 DD17 4B014 GB07 GG18 GK06 GL11 4B017 LC03 LK13 LK21 LL09 4B018 MD33 MD81 ME14 4B032 DB21 DK14 DK54 DL20 4B036 LC06 LF01 LH11 LH48 LK06 4C087 AA01 AA02 BC11 CA09 CA14 CA47 ZA55 ZC01 ZC21
Claims (6)
成分とすることを特徴とするミネラル吸収促進剤。1. A mineral absorption promoter comprising a yeast cell wall or a yeast cell wall polysaccharide as an active ingredient.
成分とすることを特徴とする貧血の予防及び改善剤。2. An agent for preventing and improving anemia, comprising a yeast cell wall or a yeast cell wall polysaccharide as an active ingredient.
成分とすることを特徴とするミネラル吸収促進ならびに
貧血の予防または改善作用を有する食品。3. A food having an effect of promoting mineral absorption and preventing or ameliorating anemia, characterized by comprising yeast cell wall or yeast cell wall polysaccharide as an active ingredient.
成分とすることを特徴とするミネラル吸収促進ならびに
貧血の予防または改善作用を有する医薬品。4. A medicament comprising a yeast cell wall or a yeast cell wall polysaccharide as an active ingredient and having an effect of promoting mineral absorption and preventing or ameliorating anemia.
成分とすることを特徴とするミネラル吸収促進ならびに
貧血の予防または改善作用を有する飲料。5. A beverage having a function of promoting mineral absorption and preventing or ameliorating anemia, characterized by comprising yeast cell wall or yeast cell wall polysaccharide as an active ingredient.
成分とすることを特徴とするミネラル吸収促進ならびに
貧血の予防または改善作用を有する飼料。6. A feed comprising a yeast cell wall or a yeast cell wall polysaccharide as an active ingredient and having an effect of promoting mineral absorption and preventing or ameliorating anemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001052882A JP2002255832A (en) | 2001-02-27 | 2001-02-27 | Mineral absorption-promoting agent and anemia- improving agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001052882A JP2002255832A (en) | 2001-02-27 | 2001-02-27 | Mineral absorption-promoting agent and anemia- improving agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002255832A true JP2002255832A (en) | 2002-09-11 |
Family
ID=18913441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001052882A Pending JP2002255832A (en) | 2001-02-27 | 2001-02-27 | Mineral absorption-promoting agent and anemia- improving agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002255832A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003090764A1 (en) * | 2002-04-24 | 2003-11-06 | Fuji Oil Company, Limited | Mineral absorption promoter |
| JP2004292382A (en) * | 2003-03-27 | 2004-10-21 | Kirin Brewery Co Ltd | Agent for promoting absorption of mineral, and agent for preventing and/or ameliorating osteoporosis |
| JP2007045714A (en) * | 2005-08-05 | 2007-02-22 | Kirin Brewery Co Ltd | Composition for ameliorating skin condition |
| WO2007143093A3 (en) * | 2006-06-02 | 2008-06-12 | Gen Mills Inc | Yeast-leavened dough compositions comprising yeast cell wall material |
| WO2009123364A1 (en) | 2008-04-03 | 2009-10-08 | Fujifilm Corporation | Mineral absorption accelerator and iron deficiency anemia improver or food composition |
| WO2022045371A1 (en) * | 2020-08-31 | 2022-03-03 | 合同会社レビアスファーマ | Composition and manufacturing method for said composition, method for improving fat-soluble component absorbability, method for improving fat-soluble component extraction efficiency, and fat-soluble component |
-
2001
- 2001-02-27 JP JP2001052882A patent/JP2002255832A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003090764A1 (en) * | 2002-04-24 | 2003-11-06 | Fuji Oil Company, Limited | Mineral absorption promoter |
| JP2004292382A (en) * | 2003-03-27 | 2004-10-21 | Kirin Brewery Co Ltd | Agent for promoting absorption of mineral, and agent for preventing and/or ameliorating osteoporosis |
| JP2007045714A (en) * | 2005-08-05 | 2007-02-22 | Kirin Brewery Co Ltd | Composition for ameliorating skin condition |
| JP4545063B2 (en) * | 2005-08-05 | 2010-09-15 | キリンホールディングス株式会社 | Skin condition improving composition |
| WO2007143093A3 (en) * | 2006-06-02 | 2008-06-12 | Gen Mills Inc | Yeast-leavened dough compositions comprising yeast cell wall material |
| WO2009123364A1 (en) | 2008-04-03 | 2009-10-08 | Fujifilm Corporation | Mineral absorption accelerator and iron deficiency anemia improver or food composition |
| WO2022045371A1 (en) * | 2020-08-31 | 2022-03-03 | 合同会社レビアスファーマ | Composition and manufacturing method for said composition, method for improving fat-soluble component absorbability, method for improving fat-soluble component extraction efficiency, and fat-soluble component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100566723C (en) | Carbohydrase inhibitor and application thereof derived from the acorn-cup plant | |
| KR101661793B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| JP4771882B2 (en) | Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same | |
| EP0382355B1 (en) | Growth promoting agent for bacteria containing pullulan with or without dextran | |
| JP5214978B2 (en) | Composition having blood pressure lowering action and / or elevation suppressing action and food and drink containing the same | |
| WO2005056035A1 (en) | Alga extract and sugar hydrolase inhibitor containing the same | |
| JP3691685B2 (en) | Blood sugar level rise inhibitor | |
| JP2002255832A (en) | Mineral absorption-promoting agent and anemia- improving agent | |
| JP4368569B2 (en) | Preventive and ameliorating agents for renal function decline | |
| CN102388031A (en) | Inhibitor for elevation of gip level | |
| CN108771246B (en) | Composition for improving immunity and restoring physiological function of patients after operation or chemotherapy | |
| JP5248023B2 (en) | Calcium absorption promoting composition | |
| JP2007217366A (en) | Composition for reducing uric acid level | |
| JP5281895B2 (en) | Calcium absorption promoter | |
| JP4673071B2 (en) | Iron-adsorptive polymer substance, iron-containing polymer substance, and production method thereof | |
| JP4034146B2 (en) | Drug side effect inhibitor | |
| JP2002275087A (en) | Antidiabetic medicine and food for preventing diabetes | |
| JP2003277273A (en) | Mineral absorption-promoting agent | |
| JP2010173962A (en) | Glycolytic enzyme inhibitor derived from wheat endosperm and cholesterol-lowering composition containing dietary fiber | |
| JP5222299B2 (en) | Fat absorption inhibiting composition | |
| JP2002193823A (en) | Medicine for preventing drunken sickness and hangover | |
| WO2008023425A1 (en) | Composition for amelioration of skin condition | |
| JP2012170342A (en) | Taste quality improver | |
| JP2009084191A (en) | Pharmaceutical composition for inhibiting appetite | |
| JP2006306897A (en) | Mozuku (edible seaweed)-originating fucoidan including agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081216 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090414 |